CPRX News and Press, Catalyst Pharmaceuticals Inc. From 04/01/24

2024-04-01 10:17:11 ET More on Solid Biosciences Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid William Blair starts Solid Biosciences at outperform Piper Sandler upgrades Solid Biosciences to overweight Seeking Alpha’s Quant ...

CORAL GABLES, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and ...

CORAL GABLES, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, t...

2024-03-21 15:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-03-14 15:09:19 ET More on Catalyst Pharmaceuticals Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2023 Earnings Call Transcript Biotech And Pharma Diversification Pays Off Catalyst Pharmaceuticals At A Crossroads: Firdapse Litigation And Agamree's Launch Catal...

2024-03-13 13:46:03 ET More on Catalyst Pharmaceuticals Catalyst Pharmaceuticals, Inc. (CPRX) Q4 2023 Earnings Call Transcript Biotech And Pharma Diversification Pays Off Catalyst Pharmaceuticals At A Crossroads: Firdapse Litigation And Agamree's Launch Catal...

AGAMREE ® (vamorolone) a Novel Alternative Corticosteroid with Demonstrated Properties in Maintaining Efficacy and a Well-Tolerated Side Effect Profile Available in the U.S. by Prescription for Patients Aged Two Years and Older Catalyst Pathways ® Program will ...

CORAL GABLES, Fla., March 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to...

Achieved Record 2023 Total Revenues of $398.2 Million, an 85.9% Increase Compared to 2022 Achieved Record Fourth Quarter 2023 Total Revenues of $110.6 Million, an 82.0% Increase Compared to Fourth Quarter 2022 Reported 2023 GAAP Net Income of $71.4 Million, $0.63 Per Share Di...

SilverBow Resorces Inc. (SBOW) is expected to report $2.36 for Q4 2023 FAT Brands Inc. Class B Common Stock (FATBB) is expected to report for quarter end 2023-12-31 Ecovyst Inc. (ECVT) is expected to report $0.2 for Q4 2023 MYR Group Inc. (MYRG) is expected to report $1.41 for Q4 2023...